慢性髓细胞白血病以血小板显著增多为首发表现1例并文献复习  

A case of chronic myeloid leukemia oneset with marked thrombocythemia and review of the literature

作　　者：刘珊[1] 李君君[1] 王甫珏 

机构地区：[1]南华大学附属第一医院血液科,湖南衡阳421000

出　　处：《中国现代医药杂志》2015年第4期30-33,共4页Modern Medicine Journal of China

摘　　要：目的探讨以血小板增多为首发表现的慢性髓细胞白血病(CML)的临床表现及生物学特点。方法对患者外周血细胞形态、骨髓细胞形态、免疫组织化学、染色体、融合基因、流式细胞术、骨髓活检进行检查。结果以血小板增多为首发表现CML与典型慢性髓细胞白血病临床表现存在差异,易误诊为原发性血小板增多症(ET)。由于CML可向加速期、急变期演变,应尽早进行有效药物干预。结论对血小板增多的患者应常规进行Ph染色体及bcr/abl融合基因检测,尽早鉴别ET及CML,避免延误治疗。Objective To study the clinical manifestations and biological features of chronic myeloid leukemia （CML） started with marked thrombocytosis. Methods Examined the patients for peripheral blood cell morphology, bone marrow cell morphology, immunohistochemistry,chromosomes, fusion gene, flow cytometry and bone marrow biopsy. Results Chronic myeloid leukemia with marked thrombocythemia had different clinical manifestations with typical chronic myeloid leukemia, and it could be easily misdiagnosed as essential thrombocythemia. CML could evolve into accelerated phase and blastic phase, should be intervened with effective drug as early as possible. Conclusion The patients manifested with thrombocythemia should be routinely detected Ph chromosome and bcr/abl fusion gene, distinguished ET from CML as soon as possible to avoid delayring treatment.

关 键 词：慢性髓细胞白血病 血小板增多 PH染色体 BCR/ABL基因 

分 类 号：R733.72[医药卫生—肿瘤]